Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Pliant Therapeutics Inc
PLRXCurrent price
1.59 USD
+0.01 USD (+0.63%)
Last closed
1.55 USD
Company
pliantrx.com
ISIN
US7291391057
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
834 911 424 USD
Yield for 12 month
-88.93 %
1Y
3Y
5Y
10Y
15Y
PLRX
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Address: 260 Littlefield Avenue, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
40.18 USDP/E ratio
–Dividend Yield
–Current Year
+1 580 000 USD
Last Year
+9 685 000 USD
Current Quarter
–
Last Quarter
–
Current Year
+1 580 000 USD
Last Year
+6 004 000 USD
Current Quarter
–
Last Quarter
-622 000 USD
Key Figures PLRX
1 year
3 years
5 years
10 years
EBITDA
-219 951 008 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-28.15 %
PEG Ratio
–
Return On Equity TTM
-47.52 %
Wall Street Target Price
40.18 USD
Revenue TTM
–
Book Value
5.68 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100.00 %
Dividend Yield
–
Gross Profit TTM
9 685 000 USD
Earnings per share
-3.35 USD
Diluted Eps TTM
-3.35 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics PLRX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History PLRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation PLRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
1 376.70
Price Sales TTM
3 050.34
Enterprise Value EBITDA
-2.54
Price Book MRQ
2.41
Financials PLRX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PLRX
For 52 weeks
10.22 USD
19.62 USD
50 Day MA
13.84 USD
Shares Short Prior Month
7 291 853
200 Day MA
13.20 USD
Short Ratio
15.30
Shares Short
7 242 084
Short Percent
12.16 %
BeatStart